BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $0.09, $0.19 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $486 million versus the consensus estimate of $446.45 million.

GUIDANCE:

BioMarin Pharma sees FY2021 revenue of $1.75-1.85 billion, versus the consensus of $1.81 billion.

Vimizim Net Product Revenues		$570			to		$610
Kuvan Net Product Revenues		$250			to		$290
Naglazyme Net Product Revenues		$365			to		$395
Palynziq Net Product Revenues		$210			to		$250
Brineura Net Product Revenues		$120			to		$140
Cost of Sales (% of Total Revenues)		23%			to		25%
Research and Development Expense		$645			to		$695
Selling, General and Administrative Expense		$725			to		$775
GAAP Net Loss		($130)			to		($80)
Non-GAAP Income (1)		$170			to		$220

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.